Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01683188
Title HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Prometheus Laboratories
Indications

melanoma

Therapies

Aldesleukin + Vemurafenib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST